Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

doi:10.1016/j.metabol.2020.154244

科研成果详情

名称	Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease
作者	Zheng, Kenneth I.1; Gao, Feng2; Wang, Xiao-Bo 3; Sun, Qing-Feng 4; Pan, Ke-Hua5; Wang, Ting-Yao 6; Chen, Yong-Ping1; Liu, Wen-Yue7; George, Jacob 8,9; Zheng, Ming-Hua1,10,11
发表期刊	METABOLISM-CLINICAL AND EXPERIMENTAL
语种	英语
原始文献类型	Letter
关键词	COVID-19 SARS-CoV-2 Obesity MAFLD
摘要	Background & aims: Coronavirus disease 2019 (COVID-19) has been declared a pandemic in 2020. Patients with metabolic associated fatty liver disease (MAFLD) are often obese and have additional metabolic risk factors which may aggravate the severity of respiratory diseases and of COVID-19. This study aims to investigate the association between MAFLD and COVID-19 severity. Methods: 214 patients with laboratory-confirmed COVID-19 aged between 18 and 75 years from three hospitals in Wenzhou, China were consecutively enrolled. Sixty-six patients with MAFLD were included in the final analysis. COVID-19 was diagnosed as a positive result by high-throughput sequencing or real-time reverse transcriptase-polymerase chain reaction assay of oropharyngeal swab specimens. COVID-19 severity was assessed during hospitalization and classified as severe and non-severe based on the current management guideline. All patients were screened for fatty liver by computed tomography and subsequently diagnosed as MAFLD according to a recent set of consensus diagnostic criteria. Obesity was defined as BMI >25 kg/m2. Results: The presence of obesity in MAFLD patients was associated with a ~6-fold increased risk of severe COVID-19 illness (unadjusted-OR 5.77, 95% CI 1.19–27.91, p = 0.029). Notably, this association with obesity and COVID-19 severity remained significant (adjusted-OR 6.32, 95% CI 1.16–34.54, p = 0.033) even after adjusting for age, sex, smoking, diabetes, hypertension, and dyslipidaemia. Conclusions: Our data demonstrate that the risk of obesity to COVID-19 severity is greater in those with, than those without MAFLD.
出版者	W B SAUNDERS CO-ELSEVIER INC
出版地	PHILADELPHIA
ISSN	0026-0495
EISSN	1532-8600
卷号	108
DOI	10.1016/j.metabol.2020.154244
页数	3
WOS类目	Endocrinology & Metabolism
WOS研究方向	Endocrinology & Metabolism
WOS记录号	WOS:000542550800005
收录类别	SCIE ; SCOPUS
发布日期	2020-07
URL	查看原文
PubMed ID	32320741
通讯作者地址	[Zheng, Ming-Hua]Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatol, MAFLD Res Ctr, 2 Fuxue Lane, Wenzhou 325000, Peoples R China. ; [George, Jacob]Westmead Hosp, Westmead Inst Med Res, Storr Liver Ctr, Westmead, NSW 2145, Australia. ; [George, Jacob]Univ Sydney, Westmead, NSW 2145, Australia.
Scopus学科分类	Endocrinology, Diabetes and Metabolism;Endocrinology
SCOPUSEID	2-s2.0-85083900952
TOP期刊	TOP期刊
引用统计	被引频次：190[WOS] [WOS记录] [WOS相关记录]
文献类型	其他
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/32469
专题	附属第一医院温州医科大学附属第一医院_内分泌科附属第一医院_肾内科附属第一医院_消化内科第一临床医学院（信息与工程学院）、附属第一医院_影像医学与核医学_放射科
通讯作者	George, Jacob; Zheng, Ming-Hua
作者单位	1.Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatol, MAFLD Res Ctr, 2 Fuxue Lane, Wenzhou 325000, Peoples R China; 2.Wenzhou Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Wenzhou, Peoples R China; 3.Wenzhou Cent Hosp, Dept Crit Care Med, Wenzhou, Peoples R China; 4.Ruian Peoples Hosp, Dept Infect Dis, Wenzhou, Peoples R China; 5.Wenzhou Med Univ, Affiliated Hosp 1, Dept Radiol, Wenzhou, Peoples R China; 6.Wenzhou Med Univ, Affiliated Hosp 1, Dept Nephrol, Wenzhou, Peoples R China; 7.Wenzhou Med Univ, Affiliated Hosp 1, Dept Endocrinol, Wenzhou, Peoples R China; 8.Westmead Hosp, Westmead Inst Med Res, Storr Liver Ctr, Sydney, NSW, Australia; 9.Univ Sydney, Sydney, NSW, Australia; 10.Wenzhou Med Univ, Inst Hepatol, Wenzhou, Peoples R China; 11.Key Lab Diag & Treatment Dev Chron Liver Dis Zhej, Wenzhou, Peoples R China
第一作者单位	附属第一医院
通讯作者单位	附属第一医院
推荐引用方式 GB/T 7714	Zheng, Kenneth I.,Gao, Feng,Wang, Xiao-Bo,et al. Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. 2020.